膀胱癌

召集人:陳柏誠主任

膀胱癌診療指引修訂

2024-12-13 修訂第十一版	2026-01-09 修訂第十二版
● 更新文獻	● 更新文獻

膀胱癌臨床診療指引-1


膀胱腫瘤
膀胱鏡檢查 ± 切片
且/或 尿液細胞學檢查
且/或 電腦斷層/核磁共振檢查
膀胱內視鏡下腫瘤切除
(考慮術後 24 小時單次膀胱內化學灌注)
非肌肉層侵犯性膀胱癌
肌肉層侵犯性膀胱癌
電腦斷層/核磁共振檢查
± 核醫骨骼掃描
有遠端轉移膀胱癌
化療
無遠端轉移膀胱癌
無局部淋巴結
有局部淋巴結
Ta, Tis, T1 (非肌肉層侵犯)
T2,T3,T4a (肌肉層侵犯)
T4b
考慮淋巴結切片
見膀胱癌診療指引-2
見膀胱癌診療指引-3
化療
化療

膀胱癌臨床診療指引-2



非肌肉層侵犯性膀胱癌風險評估：

1. 低風險: papillary urothelial neoplasm of low malignant potential, low grade UC (Ta, ≦3cm and 單一個)
2. 中風險: low grade UC (T1 or >3cm or 多個 or 一年內復發), high grade UC(Ta, ≦3cm and 單一個)
3. 高風險: high grade UC (CIS or T1 or >3cm or 多個), 其中如果有以下情形如 ① BCG無效，② variant histology，
   ③ lymphovascular invasion, ④ prostatic urethra involvement 視作非常高風險性

建議進行第二次的內視鏡下腫瘤切除的情況：

1. 在 high grade Ta 情況下，懷疑沒有切除乾淨或是標本無肌肉層
2. 所有 T1 的腫瘤
3. 腫瘤大於 3cm，或多發性腫瘤
4. T2 以上腫瘤，但標本未包含肌肉層或懷疑沒有切除乾淨

- 一般低風險性的追蹤即可，中風險性的建議膀胱灌藥或追蹤，高風險性的先嘗試膀胱灌藥或可考慮轉院灌 BCG 或膀胱全切除
- 尿液細胞學陽性，但是影像及膀胱鏡都沒有發現的病人→先在三個月內進行再次尿液細胞學檢查→如果再次細胞學陽性→考慮系統性膀胱切片以及經尿道攝護腺切片並考慮做輸尿管鏡及收集腎臟及輸尿管的尿液細胞學檢查

膀胱癌臨床診療指引-3



膀胱全切除後建議：

如果病人沒有接受術前化療，且病人是 pT3, pT4 或是有淋巴轉移，可以考慮術後化療或打 nivolumab 免疫療法

如果病人術前有化療，且病人是 pT2-T4 或是有淋巴轉移，可以考慮術後打 nivolumab

病人是 pT3, pT4 或是有淋巴轉移或是切除的不乾淨，可以考慮術後加做放射治療

化學治療處方

全身性化學治療主要採用gemcitabine 1000mg + cisplatin 70mg Q3W, 4 cycles

膀胱癌必要檢查：

1. 膀胱鏡
2. 電腦斷層或是核磁共振

膀胱癌選擇性檢查：

1. Chest X-ray
2. Bone scan
3. Urine cytology
4. Renal ultrasound
5. ureteroscopy

膀胱癌之分期(AJCC 8版)

Stage groups	N0	N1	N2	N3	M1a	M1b
Ta	0a					
Tis	0is					
T1	I	IIIA	IIIB	IIIB	IVA	IVB
T2	II	IIIA	IIIB	IIIB	IVA	IVB
pT2a	II	IIIA	IIIB	IIIB	IVA	IVB
pT2b	II	IIIA	IIIB	IIIB	IVA	IVB
T3	IIIA	IIIA	IIIB	IIIB	IVA	IVB
pT3a	IIIA	IIIA	IIIB	IIIB	IVA	IVB
pT3b	IIIA	IIIA	IIIB	IIIB	IVA	IVB
T4a	IIIA	IIIA	IIIB	IIIB	IVA	IVB
T4b	IVA	IVA	IVA	IVA	IVA	IVB

Primary tumor (T)	
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Ta	Non-invasive papillary carcinoma
Tis	Urothelial carcinoma in situ: "flat tumor"
T1	Tumor invades lamina propria (subepithelial connective tissue)
T2	Tumor invades muscularis propria
pT2a	Tumor invades superficial muscularis propria (inner half)
pT2b	Tumor invades deep muscularis propria (outer half)
T3	Tumor invades perivesical soft tissue
pT3a	Microscopically
pT3b	Macroscopically (extravesical mass)
T4a	Extravesical tumor invades directly into prostatic stroma, seminal vesicles, uterus, vagina
T4b	Extravesical tumor invades pelvic wall, abdominal wall

Regional lymph nodes (N)	
NX	Lymph nodes cannot be assessed
N0	No lymph node metastasis
N1	Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)
N2	Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis)
N3	Lymph node metastasis to the common iliac lymph nodes
Distant metastasis (M)	
M0	No distant metastasis
M1a	Distant metastasis limited to lymph nodes beyond the common iliacs
M1b	Non-lymph-node distant metastases

膀胱癌之化療診療指引

Intravesical Chemotherapy

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
M002	ECK_MDP	Mitomycin	30mg	INVE		D1,22	QW	6	1
		Doxorubicin	30mg	INVE		D8,29			
		Cisplatin	30mg	INVE		D15,36			
M001	MDP	Mitomycin	30mg	INVE		D1,22	QW	6 weeks	1
		Doxorubicin	30mg	INVE		D8,29			
		Cisplatin	30mg	INVE		D15,36			
		Mitomycin	30mg	INVE		D1	After 6 weeks, Q3M	8	
		Doxorubicin	30mg	INVE		D8			
		Cisplatin	30mg	INVE		D15			
	Doxor	Doxorubicin	50mg/20mL	INVE		D1	Q4W	12	2
	MMC	Mitomycin	40mg/50mL	INVE		D1	QW	6 weeks	3
							Q4W	12	
							Q3M	4	

10

膀胱癌之化療診療指引

Intravesical Chemotherapy

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
M005	Mitomycin C after TURBT	Mitomycin	30mg	INVE		D1		1	21-22

膀胱癌之化療診療指引

(Neo)adjuvant Chemotherapy

化療系統處方代碼	處方	藥名	劑量 (mg/m^2)	途徑	輸注時間	天數	頻率	療程數	文獻
M006 M006-1	Cisplatin+ Gemcitabine	Gemcitabine	1000	IVD	1h	D1,8	Q3W	4	5
		Cisplatin	70	IVD	2h	D1			
M011	DDMVAC	Methotrexate	30	IVD	5min	D1	Q2W	3-6	8-9
		Vinblastine	3	IVD	10min	D2			
		Doxorubicin	30	IVD	1h	D2			
		Cisplatin	70	IVD	2h	D2			

膀胱癌之化療診療指引

CCRT (bladder cancer)

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
M009	Weekly Cisplatin	Cisplatin	30	IVD	2h	D1	QW		12
M008	Weekly Carboplatin	Carboplatin	AUC2	IVD	2h	D1	QW		12

膀胱癌之化療診療指引

Chemotherapy for advanced and metastatic disease (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
	Cisplatin+ Gemcitabine	Gemcitabine	1000	IVD	1h	D1,8	Q3W	4	4、6
		Cisplatin	70	IVD	2h	D1			
M007 M007-1	Carboplatin+ Gemcitabine	Gemcitabine	1000	IVD	0.5h	D1,8	Q3W	4	7
		Carboplatin	AUC5	IVD	1h	D1			
	DDMVAC	Methotrexate	30	IVD	5min	D1	Q2W	3-6	8-9
		Vinblastine	3	IVD	10min	D2			
		Doxorubicin	30	IVD	1h	D2			
		Cisplatin	70	IVD	2h	D2			

膀胱癌之化療診療指引

Chemotherapy for advanced and metastatic disease (1st-line)

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
M015	Pembrolizumab (cisplatin ineligible)	Pembrolizumab	200mg/day	IVD	1h	D1	Q3W		10
	Gemcitabine + Cisplatin followed by Avelumab	Gemcitabine	1000	IVD	1h	D1,8,15	Q4W	6	13-14
		Cisplatin	70	IVD	2h	D1			
		followed by Avelumab	10 mg/kg	IVD	1h	D1	Q2W		
M013 M013-1	Paclitaxel+ Gemcitabine	Paclitaxel	150	IVD	1h	D1	Q3W		15
		Gemcitabine	1000	IVD	0.5h	D1,8			
	Atezolizumab (cisplatin ineligible)	Atezolizumab	1200mg/day	IVD	1h	D1	Q3W		16

膀胱癌之化療診療指引

Chemotherapy for advanced and metastatic disease (others)

化療系統 處方代碼	處方	藥名	劑量 (mg/m²)	途徑	輸注時間	天數	頻率	療程數	文獻
M012	Paclitaxel biweekly	Paclitaxel	150	IVD	1h	D1	Q2W		17
M014	Avelumab+ Docetaxel	Avelumab	10 mg/kg	IVD	1h	D1	Q3W	6	18
		Docetaxel	75 mg/kg	IVD	1.5h	D1			

膀胱癌之化療診療指引

Targeted therapy for advanced and metastatic disease (2nd-line)

化療系統處方代碼	處方	藥名	劑量 (mg/m^2)	途徑	輸注時間	天數	頻率	療程數	文獻
	Nivolumab (cisplatin ineligible)	Nivolumab	3mg/kg	IVD	1h	D1	Q2W	until disease progression	11
M010	Avelumab biweekly (cisplatin ineligible)	Avelumab	10mg/kg	IVD	1h	D1	Q2W	until disease progression	19-20

文獻

1. NCCN guideline bladder cancer Version 2.2025.
2. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer：summary of the 2013 guidelines. EUR UROL 2014:65:778-792
3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol.2000 Sep;18(17):3068-77.

化療文獻

1. Chung-Hsin Chen, Hung-Ju Yang, Chia-Tung Shun et al. (2012). "A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer." Urol Oncol,30(4):421-7.
2. Lamm DL, Blumenstein BA, Crawford ED et al. (1991). A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med, 325:1205-9.
3. Truls Gårdmark, Staffan Jahnson, Rolf Wahlquist et al. (2007) Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU International, 99:817-820.
4. B. Gunlusoya,, M. Arslana, E. Vardarb et al. (2012). The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial Carcinoma. Actas Urol Esp., 36(9):515-520.
5. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113:2471-2477.
6. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
7. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clinl Oncol 2012;30:191-199.
8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
9. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001;19:2638-2646.
10. Balar AV, Castellano DE, O'Donnell PH, et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. Clin Oncol 2017;6S:Abstract 284.
11. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312-322
12. Finek J, Holubec L Jr, Svoboda T, et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res. 2009;29(2):667-670.

13. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
14. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218-1230.
15. Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288-294.
16. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76.
17. Sideris S, Aoun F, Zanaty M, et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol. 2016;4(6):1063-1067. doi:10.3892/mco.2016.821
18. Ten Eyck JE, Kahlon N, Masih S, Hamouda DM, Petros FG. Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes. Cancer Manag Res. 2022;14:729-738. Published 2022 Feb 22. doi:10.2147/CMAR.S227323
19. Patel M, Ellerton J, Infante J, et al. Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial [abstract]. J Clin Oncol 2018;6S:Abstract 330. Patel M, Ellerton J, Infante J, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts or an open-label, phase 1 trial. Lancet Oncol 2018;19:51-64.
20. Ten Eyck JE, Kahlon N, Masih S, Hamouda DM, Petros FG. Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes. Cancer Manag Res. 2022;14:729-738. Published 2022 Feb 22. doi:10.2147/CMAR.S227323
21. Bosschieter, J., Nieuwenhuijzen, J. A., van Ginkel, T., Vis, A. N., Witte, B., Newling, D., Beckers, G. M. A., & van Moorselaar, R. J. A. (2018). Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. European urology, 73(2), 226–232. https://doi.org/10.1016/j.eururo.2017.06.038
22. Barghi, M. R., Rahmani, M. R., Hosseini Moghaddam, S. M., & Jahanbin, M. (2006). Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder. Urology journal, 3(4), 220–224